Evidence map›Paper›PMID 10815773›Full record

ArticleJournal of computer-aided molecular design2000

Conformational analysis of a farnesyltransferase peptide inhibitor, CVIM.

L Carlacci

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of computer-aided molecular design, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

L CarlacciDepartment of Chemistry, University of South Florida, Tampa 33620, USA. lou@finch.cas.usf.edu
University of South Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The conformational states of the peptide Cys-Val-Ile-Met (or CVIM) were computed and characterized. CVIM inhibits farnesylation of the Ras oncogene product, p21ras, at the cysteine residue of the C-terminal segment. CVIM is active in an extended conformation. A similar peptide (KTKCVFM) appears to bind the enzyme in the Type I bend conformation. In the present study, the conformations of CVIM were computed in an aqueous environment with the peptide in the zwitterionic state. Solvation free energy based on solvent accessible surface area and a distance dependent dielectric were used in the calculations. Final conformations of multiple independent Monte Carlo simulated annealing (MCSA) conformational searches were used as starting points for Metropolis Monte Carlo (MMC) runs. Conformations saved at intervals during MMC runs were analyzed. Conformers were separated by interactive clustering in dihedral angle coordinates. The four lowest energy conformers corresponding to a Type I bend, extended, AB-bend, and BA-bend were within 0.3 kcal/mol of each other, and dominant in terms of population. The Type I bend and extended conformers were supported by the binding studies. The extended conformer was the most populated. In the AB-bend conformer, 'A' indicates the alpha-helix conformation of Val, and 'B' indicates the beta-strand conformation of Ile. The AB- and BA-bend conformations differed from the extended conformation in the value of Val psi and Ile psi, respectively, and from the Type I bend conformation in the value of Ile psi and Val psi, respectively. The four lowest energy conformers were characterized in terms of energy, density of low energy conformations (or entropy), structure, side chain rotamer fraction population, and interatomic distances.

Indexed as

Alkyl and Aryl TransferasesAmino Acid SequenceComputer SimulationDrug DesignEnzyme InhibitorsFarnesyltranstransferaseIn Vitro TechniquesOligopeptidesProtein ConformationProto-Oncogene Proteins p21(ras)Static ElectricityThermodynamicsAlkyl and Aryl Transferasescysteinyl-valyl-isoleucyl-methionineEnzyme InhibitorsFarnesyltranstransferaseOligopeptidesProto-Oncogene Proteins p21(ras)

Identifiers

PMID10815773
OpenAlexW1489467936

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.